How to carry out retrospective studies in metastatic renal cell cancer: Two caveats that should be avoided

Giuseppe Di Lorenzo, Matteo Ferro, Carlo Buonerba

Research output: Contribution to journalArticle

Abstract

Evaluation of: Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.

Original languageEnglish
Pages (from-to)331-333
Number of pages3
JournalExpert Review of Anticancer Therapy
Volume12
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Renal Cell Carcinoma
Retrospective Studies
Vascular Endothelial Growth Factor A
Retreatment
Therapeutics
Kidney Neoplasms
Interferons
Disease-Free Survival
Survival
Everolimus
Neoplasms

Keywords

  • kidney cancer
  • retrospective study
  • sorafenib
  • sunitinib
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

How to carry out retrospective studies in metastatic renal cell cancer : Two caveats that should be avoided. / Di Lorenzo, Giuseppe; Ferro, Matteo; Buonerba, Carlo.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 3, 03.2012, p. 331-333.

Research output: Contribution to journalArticle

@article{f7d3362a809547399677275644f6bb75,
title = "How to carry out retrospective studies in metastatic renal cell cancer: Two caveats that should be avoided",
abstract = "Evaluation of: Gr{\"u}nwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.",
keywords = "kidney cancer, retrospective study, sorafenib, sunitinib, targeted therapy",
author = "{Di Lorenzo}, Giuseppe and Matteo Ferro and Carlo Buonerba",
year = "2012",
month = "3",
doi = "10.1586/era.11.215",
language = "English",
volume = "12",
pages = "331--333",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - How to carry out retrospective studies in metastatic renal cell cancer

T2 - Two caveats that should be avoided

AU - Di Lorenzo, Giuseppe

AU - Ferro, Matteo

AU - Buonerba, Carlo

PY - 2012/3

Y1 - 2012/3

N2 - Evaluation of: Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.

AB - Evaluation of: Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S. Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br. J. Cancer 105(11), 1635-1639 (2011). The results achieved with targeted therapy have changed the natural course of kidney cancer not amenable to local therapy. Sunitinib, bevacizumab and pazopanib are approved in the first-line setting for patients at good/intermediate prognosis, while temsirolimus should be the first-line agent to be used in patients at poor prognosis. The oncology community has been eagerly awaiting results as far as second-line treatment is concerned. The RECORD-1 and AXIS trials provided evidence in favor of everolimus and axitinib, respectively, in patients pretreated with VEGF-directed agents. As the number of available agents grows, so does the possibility of using multiple lines of therapy with a potential benefit in overall survival. The third-line setting has been poorly investigated, and no comparative prospective trials are presently available. Retreatment with VEGF-directed therapy may be an option in everolimus-pretreated patients, with the possibility that mTOR inhibitors may reverse resistance to VEGF-directed therapy. Grunwald et al. presented retrospective data showing that retreatment with VEGF-directed targeted agents, including sunitinib, bevacizumab/interferon, dovitinib and sorafenib, was associated with a progression-free survival time of approximately 5 months. Although the evidence provided by retrospective studies is weak, their role in highlighting matters of clinical relevance deserving investigation is undoubtful, as demonstrated by the retrospective study discussed in this paper.

KW - kidney cancer

KW - retrospective study

KW - sorafenib

KW - sunitinib

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84857852978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857852978&partnerID=8YFLogxK

U2 - 10.1586/era.11.215

DO - 10.1586/era.11.215

M3 - Article

C2 - 22369324

AN - SCOPUS:84857852978

VL - 12

SP - 331

EP - 333

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -